Capital Markets Open To Health Care, But Just A Crack, Panelists Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent biotech IPO activity and venture capital investment signals momentum shift in the capital markets, though instability remains, according to panelists at the BIO CEO & Investor conference.
You may also be interested in...
Biopharma Quarterly Statistics Q1 2010
In Vivo presents another quarterly review of pharmaceutical/biotechnology dealmaking - for the first quarter of 2010. Our data come from Elsevier's Strategic Transactions. During the first quarter of 2010, biopharma companies raised $2.6 billion through 94 transactions, slightly better than last year's opening, but a decrease of 43% from Q4 2009. Early venture capital rounds were the most popular type of financings, followed closely by follow-on public offerings and private investments in public companies, but FOPOs clearly brought in the most money, $1.1 billion.With less than half the M&A deal volume of the previous quarter - however, about the same dollar figure - Q1 2010's 12 transactions brought in $7.1 billion.
Biopharma Quarterly Statistics Q1 2010
In Vivo presents another quarterly review of pharmaceutical/biotechnology dealmaking - for the first quarter of 2010. Our data come from Elsevier's Strategic Transactions. During the first quarter of 2010, biopharma companies raised $2.6 billion through 94 transactions, slightly better than last year's opening, but a decrease of 43% from Q4 2009. Early venture capital rounds were the most popular type of financings, followed closely by follow-on public offerings and private investments in public companies, but FOPOs clearly brought in the most money, $1.1 billion.With less than half the M&A deal volume of the previous quarter - however, about the same dollar figure - Q1 2010's 12 transactions brought in $7.1 billion.
Health Reform 101: Cashing In On Hidden Financial Aid Provisions
Biopharmas could win grants equivalent to half of their research expenses in 2009 and 2010, plus apply for a slice of the $500 million in new R&D funding available in areas of high medical need, courtesy of the health reform package